Mutual ATRaction: Assessing Synergy of Berzosertib with Sacituzumab Govitecan.
case_series · Level IV
Where this comes from
- Record sourced from PubMed, PMID 37439710.
- Also identified by DOI 10.1158/1078-0432.CCR-23-1422.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
A phase I trial of the novel combination of the ataxia telangiectasia and Rad3-related inhibitor berzosertib plus the antibody-drug conjugate sacituzumab govitecan in patients with heavily pretreatment tumors demonstrated some antitumor activity and no dose-limiting toxicities. This represents a new treatment paradigm that will be further explored in a phase II setting. See related article by Abel et al., p. 3603.
Medical subject headings
- Immunoconjugates
- Neoplasms